Skip to content

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Please ensure you fully understand the risks involved. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Please ensure you fully understand the risks involved.

Pfizer share price: what to expect from Q1 result

In this article we find out what we can expect from the upcoming Pfizer results, how they could affect the Pfizer share price as well as how to trade the  earnings.

Video poster image

When is Pfizer earnings date?

The Pfizer earnings release date is scheduled for the 4 May. The results will cover the groups quarter one (Q1) financial year 2021 (FY21) earnings (January to March 2021).

Pfizer results preview: what does the Street expect?

Pfizer, the research based global biopharmaceutical company, is expected to see low double digit revenue growth for Q1 2021 when compared to the prior year’s comparative period (Q1 2020), although earnings per share for the period are expected to be relatively flat against the comparative due to an increased cost base.

The average estimates for the upcoming results are as follows:

How to trade Pfizer Q1 results

The two graphics below provide traders with both a retail short-term view on the stock, as well as an institutional longer-term view on the Pfizer share price, as to how market participants are positioned ahead of the Q1 earnings release.

Pfizer Q1 broker recommendations Source: IG charts
Pfizer Q1 broker recommendations Source: IG charts

A Refinitiv poll of 22 analysts maintain a long-term average rating of ‘hold’ for Pfizer (as of 3 May), with two of these analysts recommending a strong buy, five recommending a buy, 15 hold, zero sell and zero strong sell recommendations on the stock.

Pfizer Q1 sentiment Source: IG charts
Pfizer Q1 sentiment Source: IG charts

From a retail trader perspective (as of 3 May), 99% of IG clients with open positions on the Pfizer expect the share price to rise over the near term, while 1% of IG clients with open positions expect the Pfizer price to fall.

Pfizer share price: technical analysis

Pfizer Q1 technical analysis Source: IG charts
Pfizer Q1 technical analysis Source: IG charts

The Pfizer share price is currently testing resistance of the $33.40 to $39.30 range within which it currently trades.

For a bullish trading scenario, traders will want to see a confirmed (with a daily close) break of the $39.30 level, before targeting a move to the near term high at $42.90. In this scenario, a close below the dotted trend line may be used as a stop loss consideration.

For a bearish trading scenario, a close below the dotted trend line support could indicate that the price is now looking to return to range support at $33.40. In this scenario, $33.40 becomes the downside target, while a close above range resistance at $39.30 could be used as a stop loss consideration for the trade.

In summary

  • Pfizer Q1 FY21 results are scheduled for release on the 4 May
  • Group revenue for the quarter is expected to be realized at $13.6 billion
  • EPS for the quarter is expected to be realized at $0.78
  • The majority of IG clients with open positions on Pfizer expect the price to rise in the near term
  • A technical analysis view on the Pfizer share price shows a short to medium-term rangebound price environment

This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get commission from just 0.08% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.